KOSDAQBiotech & Pharma138610

Nibec

₩16,030▼ 1.72%2026-10-02 close

Market Cap

₩181.7B

Turnover

₩500M

Volume

30,000 shares

Shares out.

11.4M

PER

—

PBR

3.5×

EPS

-₩2

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Core Growth Continues Beyond the Licensing Windfall

Nibec swung to profitability in 2025 on a US licensing deal for its fibrosis drug candidate, and as that one-off effect fades in 2026, growth in its core tissue-regeneration biomaterials business and the prospect of follow-on licensing deals for its pipeline have become the key variables for earnings and valuation.

1
The upfront payment from the 2025 NP-201 (now ORJ-001) licensing deal drove annual operating profit to a positive turn and sharply improved the debt ratio.
2
In 2026, revenue and profit scaled back as the base effect of the licensing upfront payment faded, but the core tissue-regeneration biomaterials business kept posting double-digit growth.
3
ORJ-001 received FDA approval to proceed with a Phase 2 trial in the US, and the company is preparing a clinical trial application (CTA) to run a parallel Phase 2 in Europe.
4
At BIO USA 2026, the company presented follow-on pipeline assets such as Regenotide and NIPEP-401 to global pharmaceutical firms including Pfizer and AbbVie, targeting confidentiality agreements (CDAs) within the third quarter and material transfer agreements (MTAs) by year-end.
5
A history of convertible bond conversion-price adjustments and rights offerings means potential future share dilution is a factor worth monitoring.

Business structure

Nibec is a biotechnology company founded in 2004 and listed on KOSDAQ in 2011 under the technology special listing track, running a dual structure of dental tissue-regeneration biomaterials and peptide drug development.

Its core revenue base consists of dental and oral-surgery tissue-regeneration materials including the OCS-B and GuidOss bone graft substitutes and the collagen-based periodontal regeneration material Regenomer, and as of 2024 exports of 20.1 billion won accounted for about 81.9% of total revenue of 24.6 billion won.

Its main export products are dental tissue-regeneration biomaterials, with global sales expanding across China, Europe and North America.

The second pillar is its proprietary cell/tissue-penetrating peptide platform NIPEP-TPP and the drug pipeline built on it, including the pulmonary fibrosis candidate ORJ-001 (formerly NP-201), the obesity/MASH candidate Regenotide, and the chronic kidney disease candidate NIPEP-401.

The company is also preparing a contract development and manufacturing (CDMO) business leveraging its peptide active pharmaceutical ingredient GMP facility.

Competitively, the dental tissue-regeneration segment faces numerous domestic and global implant and bone-graft material makers, while the peptide drug-delivery and CDMO space includes large global peptide contract manufacturers and domestic peptide specialists.

For its drug pipeline, the company has favored an early out-licensing strategy over running its own late-stage trials, shifting development risk to partner firms. This dual structure combines a legacy materials business that provides steady cash flow with a higher-risk, higher-potential drug licensing business.

Earnings trend

Quarterly revenue · Operating profit

₩15.8B₩8.4B25Q2₩5.2B-₩1B25Q3₩6.1B-₩1.2B25Q4₩5.2B₩100M26Q1₩6.1B₩100M26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩21.7B₩600M2022₩15.7B-₩2.2B2023₩24.6B-₩4.9B2024₩32.7B₩5B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩15.8B	₩8.4B	53.1%
2025Q3	₩5.2B	-₩1B	−19.2%
2025Q4	₩6.1B	-₩1.2B	−18.8%
2026Q1	₩5.2B	₩100M	2.6%
2026Q2	₩6.1B	₩100M	1.7%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩21.7B	₩600M	-₩3.8B	3.0%	−11.4%	114.7%
2023	₩15.7B	-₩2.2B	-₩6.3B	−14.2%	−21.8%	131.6%
2024	₩24.6B	-₩4.9B	-₩9.3B	−20.1%	−28.9%	93.8%
2025	₩32.7B	₩5B	₩4.6B	15.4%	10.1%	37.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-24

Earnings analysis

Nibec's annual results moved from a loss-making pattern in 2022-2024 to a clear profit turnaround in 2025.

In 2022, revenue was KRW 21.7 billion with operating profit of KRW 0.65 billion (operating margin 3.0%), yet net income was still negative at KRW -3.77 billion; in 2023, revenue fell to KRW 15.7 billion with an operating loss of KRW 2.23 billion (margin -14.2%) and a net loss of KRW 6.28 billion as the downturn deepened.

In 2024, revenue recovered to KRW 24.55 billion, but the operating loss widened to KRW 4.93 billion (margin -20.1%) and the net loss expanded to KRW 9.33 billion.

In 2025, revenue reached KRW 32.72 billion with operating profit of KRW 5.03 billion (margin 15.4%) and net income of KRW 4.64 billion, a clear turnaround, while the debt ratio dropped sharply from 93.8% in 2024 to 37.5% in 2025 and operating cash flow improved to KRW 5.82 billion.

The core driver of this turnaround was the licensing upfront payment concentrated in the second quarter of 2025, when revenue hit KRW 15.8 billion, operating profit KRW 8.39 billion, and net income KRW 7.70 billion, effectively carrying the full-year result.

Once that one-off effect faded, the company returned to operating losses in the third quarter of 2025 (revenue KRW 5.17 billion, operating loss KRW 0.99 billion, net loss KRW 0.45 billion) and the fourth quarter (revenue KRW 6.14 billion, operating loss KRW 1.15 billion, net loss KRW 1.10 billion).

Entering 2026, the company returned to modest operating profitability in the first quarter (revenue KRW 5.24 billion, operating profit KRW 0.14 billion, net income KRW 1.15 billion) and the second quarter (revenue KRW 6.06 billion, operating profit KRW 0.10 billion, net income KRW 0.38 billion), with net income notably larger than operating profit in both quarters, a pattern attributable to non-operating items.

Summed over the most recent four quarters (Q3 2025 through Q2 2026), net income is close to breakeven, reflecting the fact that the large one-off gain from Q2 2025 has since rolled out of that trailing window — a point worth keeping in mind when assessing the sustainability of future results.

Industry analysis

The dental tissue-regeneration biomaterials market continues to grow moderately, driven by an aging population and rising implant demand, and Nibec has positioned itself with a high export share across China, Europe, and North America.

The company has also been expanding its regulatory footprint, recently obtaining EU Medical Device Regulation (MDR) certification, extending its Brazilian product approvals, and pursuing market entry approval in Japan.

In the drug pipeline segment, Nibec's NP-201/ORJ-001 deal sits within a broader wave of Korean biotech out-licensing deals; around the same period, Olix struck a licensing deal with Eli Lilly and Y-Biologics with LegoChem Biosciences, illustrating that global partnering by Korean biotechs has become an industry-wide trend.

In the obesity and metabolic disease treatment market, there is strong demand to address side effects of GLP-1 class drugs such as vomiting and indigestion, keeping big pharma interest high in muscle-sparing, multi-mechanism peptide candidates.

The peptide CDMO market is also growing on the back of expanding peptide drug demand including obesity treatments, though it remains a competitive field with large global contract manufacturers and domestic rivals.

By running a stable cash-generating materials business alongside a higher-growth, higher-risk peptide drug licensing business, Nibec occupies a different position from competitors that depend solely on the materials business.

Outlook

The company plans total capital expenditure of KRW 3 billion over 2025-2026 (KRW 2 billion in 2025, KRW 1 billion in 2026) to build out its peptide CDMO business.

For its flagship pipeline ORJ-001, partner Oorja Bio received FDA approval in May to proceed with a Phase 2 trial, and the company is preparing a clinical trial application (CTA) to run a parallel Phase 2 in Europe as part of its commercialization strategy.

Clinical drug supply is proceeding in stages, making the timing of trial initiation in the US and Europe a key item to watch.

At the BIO International Convention 2026 (BIO USA 2026) held in San Diego in June, the company said it held discussions on licensing, joint clinical development, and commercialization for its oncology and metabolic disease pipeline with global pharmaceutical companies including Pfizer and AbbVie.

Based on the outcomes of those meetings, the company said it would select priority partner candidates, complete confidentiality agreements (CDAs) and detailed data package delivery within the third quarter, and coordinate efficacy verification testing and technical due diligence with some companies through material transfer agreements (MTAs) to be signed within the year.

Among the follow-on pipeline assets presented, the obesity/MASH candidate Regenotide showed fewer side effects than GLP-1 class drugs in a Phase 1 (SAD/MAD) trial, while the chronic kidney disease candidate NIPEP-401 has presented preclinical and Phase 1 data suggesting potential as a new treatment option.

In its dental materials business, the company recently obtained an additional Brazilian approval for its bone graft-collagen composite material OCS-B Collagen, broadening its product portfolio in Latin America.

Valuation

PER

—

PBR

3.5×

ROE

0.0%

EPS

-₩2

BPS

₩4,296

Dividend per share

₩0

Net income summed over the most recent four quarters has fallen close to breakeven largely because the large licensing upfront payment concentrated in the second quarter of 2025 has since rolled out of that calculation window, meaning quarter-to-quarter results carry considerable volatility.

This volatility tends to make the market weigh pipeline clinical and licensing progress more heavily than any single quarter's results when assessing the company.

Rather than dividends, the company's structure relies mainly on drug pipeline clinical progress and follow-on licensing deals as the primary channel through which enterprise value can change.

The shares trade at a level that is not low relative to net asset value, which can be interpreted as reflecting market expectations not only for the steady cash flow from the tissue-regeneration materials business but also for the potential technology value embedded in the drug pipeline.

That said, such expectations remain contingent on whether and when actual follow-on agreements — CDAs, MTAs, or new out-licensing deals — are concluded.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-24

Bull factors

A Proven Out-Licensing Monetization Model

The ORJ-001 (formerly NP-201) deal is structured with an $8 million upfront payment (about KRW 10.9 billion), up to $427 million in milestones (about KRW 584.3 billion), and a 4% royalty on net sales.

Notably, the deal shifts clinical, regulatory, and commercialization responsibilities to the partner, allowing Nibec to realize technology value without bearing development risk. This deal was instrumental in turning the company's full-year 2025 results profitable.

If similar structures are replicated for the follow-on pipeline, they could provide a repeatable non-dilutive cash inflow channel.

Steady Growth in the Core Business

In the second quarter of 2026, revenue from the core tissue-regeneration biomaterials business reached KRW 6.0 billion, up 23% year-on-year, maintaining a solid growth trend.

The company also continues to diversify its export markets, recently obtaining EU MDR certification and an additional Brazilian approval for OCS-B Collagen, while pursuing regulatory approval to enter the Japanese market.

Even as the licensing upfront effect has faded, this core business growth has acted as a factor supporting the floor of overall results.

A Diversified Follow-On Pipeline with Big Pharma Access

At BIO USA 2026, Nibec said it held discussions with global pharmaceutical companies including Pfizer and AbbVie on licensing, joint clinical development, and commercialization for its oncology and metabolic disease pipeline.

The obesity/MASH candidate Regenotide showed potential to reduce side effects associated with existing GLP-1 class drugs in a Phase 1 trial, while the chronic kidney disease candidate NIPEP-401 also presented potential as a new treatment option.

Building on these discussions, the company is targeting CDAs within the third quarter and MTAs by year-end, raising the possibility of further out-licensing outcomes.

Bear factors

Earnings Volatility as the One-Off Effect Fades

After the large upfront payment recognized in the second quarter of 2025, the company swung back to operating losses of KRW 0.99 billion and KRW 1.15 billion in the third and fourth quarters, respectively.

Modest operating profit returned in the first and second quarters of 2026, but the scale remains small, leaving open the question of whether the core business alone can sustain a stable profit trajectory.

The fact that net income summed over the trailing four quarters came in near breakeven also illustrates this volatility.

Timing Uncertainty from Conditional Milestone Structure

The development and commercialization milestones in the ORJ-001 deal are payable only after the partner achieves clinical success or obtains marketing approval and then reaches cumulative sales targets.

Unlike typical licensing deals that pay milestones at clinical-stage or regulatory filing/approval junctures, Nibec's contract specifies milestones tied to cumulative sales achievement, meaning the bulk of the cash inflow could be deferred until after commercialization. This raises uncertainty around the timing of milestone realization.

Ongoing Capital Raises and Dilution History

The company has repeatedly adjusted its convertible bond conversion prices following rights offerings priced below market, and in the first half of 2026 it carried out an additional rights offering with a public subscription of unsubscribed shares.

While such continued capital-raising activity is positive for funding business expansion, it is also a factor existing shareholders need to weigh alongside the possibility of equity dilution.

Risk factors

Pipeline and Clinical Execution Risk

Even after out-licensing, actual value realization depends on partner Oorja Bio's progress in the Phase 2 trial and on approval of the European CTA.

The CDAs and MTAs discussed at BIO USA 2026 remain at the negotiation stage rather than finalized agreements, and there is a possibility they may not materialize into signed contracts. Clinical delays or failure to reach agreements could push back the expected timeline for further monetization.

Capital Structure and Dilution Risk

The convertible bond conversion price has been repeatedly adjusted in line with share price movements, and an additional rights offering took place in 2026, embedding the potential for further share count increases.

As a small-cap KOSDAQ stock, liquidity and price volatility tend to be elevated, meaning both results and share price can react sensitively to changes in capital market conditions.

Competitive and Market Access Risk

The dental tissue-regeneration materials market is a mature market with numerous domestic and international competitors, where price competition persists, and entry into new markets such as Japan remains uncertain as regulatory approval procedures are still underway.

The peptide CDMO and drug-delivery platform space also requires competing against large global contract manufacturers and domestic rivals.

What to watch next

Late September 2026
This is when to check whether the company has completed confidentiality agreements (CDAs) and data package delivery with priority partner candidates identified following BIO USA 2026.
Mid-to-late November 2026 (expected Q3 earnings release)
Investors should check third-quarter results to see whether growth in the core tissue-regeneration biomaterials business continues and whether new revenue sources such as CDMO have begun contributing.
Fourth quarter of 2026
This period is when to confirm whether the European clinical trial application (CTA) for ORJ-001 is approved and when the first patients are dosed in the US and European Phase 2 trials.
By the end of December 2026
It is worth checking whether the material transfer agreement (MTA) targets discussed with some big pharma and biotech firms at BIO USA 2026 are actually achieved by this deadline.

Overall view

Nibec is built on two pillars: a stable cash-generating dental tissue-regeneration biomaterials business and an early out-licensing strategy for its peptide-platform drug pipeline.

The year 2025 was an inflection point, as the upfront payment from the ORJ-001 licensing deal with its US partner drove a full-year profit turnaround and improved debt ratio, but as that one-off effect faded in 2026, net income summed over the trailing four quarters returned to near breakeven.

Even so, the core tissue-regeneration biomaterials business kept posting double-digit growth during this period, and the company has continued expanding its regulatory footprint into Europe, Brazil, and Japan.

On the drug pipeline side, FDA approval for ORJ-001's US Phase 2 trial, preparations for a parallel European trial, and ongoing global partnering discussions for follow-on pipeline assets such as Regenotide and NIPEP-401 following BIO USA 2026 could provide leads for further monetization.

That said, factors worth watching include the fact that milestones are contingent on cumulative sales targets, that CDAs and MTAs remain at the negotiation stage rather than signed agreements, and that convertible bond adjustments and rights offerings have continued, keeping dilution a persistent possibility.

Overall, with a structure combining a stable core business and a higher-growth, higher-risk drug licensing business, whether and when follow-on agreements are actually concluded will likely be the key variable shaping the company's future results and business trajectory. This report is for informational purposes only and does not constitute a buy or sell recommendation.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.